The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Open accessAbstract
Calcific aortic valve disease (CAVD) is a highly prevalent condition that comprises a disease continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling, culminating in aortic stenosis, heart failure, and ultimately premature death. Traditional risk factors, such as hypercholesterolaemia and (systolic) hypertension, are shared among atherosclerotic cardiovascular disease and CAVD, yet the molecular and cellular mechanisms differ markedly. Statin-induced low-density lipoprotein cholesterol lowering, a remedy highly effective for secondary prevention of atherosclerotic cardiovascular disease, consistently failed to impact CAVD progression or to improve patient outcomes. However, recently completed phase II trials provide hope that pharmaceutical tactics directed at other targets implicated in CAVD pathogenesis offer an avenue to alter the course of the disease non-invasively. Herein, we delineate key players of CAVD pathobiology, outline mechanisms that entail compromised endothelial barrier function, and promote lipid homing, immune-cell infiltration, and deranged phospho-calcium metabolism that collectively perpetuate a pro-inflammatory/pro-osteogenic milieu in which valvular interstitial cells increasingly adopt myofibro-/osteoblast-like properties, thereby fostering fibro-calcific leaflet remodelling and eventually resulting in left ventricular outflow obstruction. We provide a glimpse into the most promising targets on the horizon, including lipoprotein(a), mineral-binding matrix Gla protein, soluble guanylate cyclase, dipeptidyl peptidase-4 as well as candidates involved in regulating phospho-calcium metabolism and valvular angiotensin II synthesis and ultimately discuss their potential for a future therapy of this insidious disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple clinical trials, focusing on lipid-lowering therapies and other targets, such as dipeptidyl peptidase-4 inhibitors, have been unsuccessful in halting CAVD progression [8,9].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Macrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., & Karsenty, G. (1997) · Nature · doi:10.1038/386078a0 · Cited by 2,120
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Mutations in NOTCH1 cause aortic valve disease
Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03940 · Cited by 1,509
Aortic Stenosis in the Elderly
Osnabrugge, R. L. J., Mylotte, D., Head, S. J., Van Mieghem, N. M., Nkomo, V. T., LeReun, C. M., Bogers, A. J. J. C., Piazza, N., & Kappetein, A. P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.015 · Cited by 1,378
Otto, C. M., Kuusisto, J., Reichenbach, D. D., Gown, A. M., & O'Brien, K. D. (1994) · Circulation · doi:10.1161/01.cir.90.2.844 · Cited by 1,315
Cited by
Lumican promotes calcific aortic valve disease through H3 histone lactylation
Huang, Y., Wang, C., Zhou, T., Xie, F., Liu, Z., Xu, H., Liu, M., Wang, S., Li, L., Chi, Q., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae407 · Cited by 124
Calcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
Self-citationLarge-scale proteomics identifies novel biomarkers and circulating risk factors for aortic stenosis
Shelbaya, K., Arthur, V., Yang, Y., Dorbala, P., Buckley, L., Claggett, B., Skali, H., Dufresne, L., Yang, T.-Y., Engert, J. C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.11.021 · Cited by 41
Self-citationSmall, A. M., Melloni, G. E. M., Kamanu, F. K., Bergmark, B. A., Bonaca, M. P., O’Donoghue, M. L., Giugliano, R. P., Scirica, B. M., Bhatt, D., Antman, E. M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0011 · Cited by 23
Song, G.-Y., Guo, X.-N., Yao, J., Lu, Z.-N., Xie, J.-H., wu, F., He, J., Fu, Z.-L., & Han, J. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03311-x · Cited by 11
Metadata
- Authors
- Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F.
- Affiliations
- University of Zurich (CH)
- Brigham and Women's Hospital (US)
- Corresponding author
- Lüscher, Thomas F
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-11-25
- Volume
- 43
- Issue
- 7
- Pages
- 683-697
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC8843796
- OpenAlex
- W3215076242
- Cited by
- 281
- References
- 214
- Citations by year
- 2026: 59 · 2025: 78 · 2024: 81 · 2023: 35 · 2022: 28
- FWCI
- 24.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Swiss Heart Foundation (FF20094)
- Foundation of Cardiovascular Research—Zurich Heart House
- National Institutes of Health (R01HL136431, R01HL141917, R01HL147095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- calcific aortic valve disease, aortic stenosis, valve calcification, endothelial barrier dysfunction, immune cell infiltration, valvular interstitial cells, osteoblast-like differentiation, left ventricular outflow tract obstruction, lipoprotein(a), matrix Gla protein, soluble guanylate cyclase, dipeptidyl peptidase IV, angiotensin II, statins, atherosclerosis, inflammation, therapeutic target
- MeSH terms
- Aortic Valve, Aortic Valve Stenosis, Calcinosis, Cells, Cultured, Humans, Osteogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. https://app.cochat.ai/papers/10.1093/eurheartj/ehab757
- The paper
- Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022). Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.